Fundraising Fox

Cellphire

Rockville, US · Founded 2005 · Delaware corporation · 48 employees on LinkedIn · 2 known investors

Find your way into Cellphire

723 people in our graph share verified history with the Cellphire team — schools, employers, funds. One of them is your warm intro.

Dominic Jacquessonunlockedknows Michael Gaffney · together at University of Oxford (overlapped)
×4knows the team · via University of Oxford
×6knows the team · via McKinsey & Company
knows the team · via United States Naval Academy

Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

BiotechMedical Devices

Founders & leadership

MGMichael Gaffney
Michael GaffneyinChief Executive OfficerMichael Gaffney is an executive with background in private equity and healthcare services, including health insurance, healthcare IT, and outsourced services. He holds a BS from the US Naval Academy and an MA from Oxford University, and previously served as a nuclear submarine officer.
DH
David HirshNamed on SEC filing
CW
Cristiane WolfeNamed on SEC filing
AH
Angela HowertonNamed on SEC filing
RW
Rob WoodsNamed on SEC filing

Board

PC
Pamela ConleyBoard director
RJ
Rafael JordainBoard Director
TD
Thomas DubinBoard director
DW
Derek WoodsBoard director
RSRandall Stanicky
Randall StanickyinBoard Member
JP
James PeakeBoard director

Investors · 2

Circadian VenturesAtlanta · $500K – $1.5M
Manta Ray VenturesLondon

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 2 rounds · 2023–2025

▶$3MraisedDec 2025 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pamela ConleyDirector
  • Rafael JordaDirector
  • Thomas DubinDirector
  • Michael GaffneyExecutive Officer, Director
  • Derek WoodsDirector
  • Randall StanickyDirector
  • James PeakeDirector
Offering amount
$3M
Amount sold
$3M
Minimum investment
$17.7K
First sale
Nov 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David HirshDirector
  • Cristiane WolfeExecutive Officer
  • Michael GaffneyExecutive Officer, Director
  • Rafael JordaDirector
  • Derek WoodsDirector
  • James PeakeDirector
  • Thomas DubinDirector
  • Angela HowertonExecutive Officer
  • Pamela ConleyDirector
  • Rob WoodsExecutive Officer
Offering amount
$8M
Amount sold
$2M
Minimum investment
$100K
First sale
Sep 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Spyre Therapeutics17 shared keywordsSpyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
Click Therapeutics16 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Kite Pharma14 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

Companies competing with Cellphire for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of DefenseSpecial Operations CommandPhase I2017$149.6K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Cellphire Therapeutics closes $15M Series A - Drug Delivery Businessdrugdeliverybusiness.com · Apr 2021Cellphire Therapeutics, Inc. Closes $15 Million Series A Funding Round Led by Simcah Managementstreetinsider.com

Frequently asked questions

What does Cellphire do?
Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.
Who are Cellphire's investors?
Cellphire's investors include Circadian Ventures, Manta Ray Ventures.
How much funding has Cellphire raised?
Cellphire has disclosed $5M raised across 2 rounds.
Where is Cellphire headquartered?
Cellphire is headquartered in Rockville, US.